Oncolytic Virus Biosafety & Characterization

Oncolytic Virus Safety and Characterization Testing

Viral-therapeutic biosafety, adventitious-agent, genetic-stability, microbial, and release-support testing for oncolytic-virus programs.

Request a Quote Contact a Scientific Project Manager

Modality > Biologics > Oncolytic Virus Safety Testing

Program Overview

Oncolytic-virus and related viral-therapeutic programs require careful control of adventitious contamination, replication-related risk, genetic stability, microbial safety, and product-specific release documentation. HyQure supports these programs through in vitro or in vivo virus-testing pathways where relevant, molecular testing platforms such as qPCR/ddPCR/NGS, replication-competent and contaminant-control pathways when applicable, and controlled reporting for sponsor quality review.

Why HyQure - Advantages

Adventitious-agent and virus-testing coverage

In vitro virus testing, in vivo virus testing where justified, and broad contaminant-control language remain central, rather than unsupported tumor-selectivity or shedding claims.
Genetic-stability and molecular support

qPCR, ddPCR, NGS, TEM, and related molecular platforms can be presented as tools that support viral-therapeutic biosafety investigations.
Replication-related risk control

Where relevant to the platform, describe replication-competent or contaminant-control pathways with careful product-specific wording.
Method and report control

Custom method development and validation support may be described only in the context of supported virus-testing and biosafety workflows.

Supported Oncolytic-Virus Testing Scope

In vitro / in vivo virus testing

In vitro assay coverage and in vivo virus-testing capability, including MAP/HAP/RAP and related inoculation pathways where justified.
Genetic stability and molecular biosafety:

qPCR/ddPCR/NGS/TEM-enabled investigation of viral identity, genetic stability, or contaminant risk according to the agreed scope.
Microbial and adventitious-agent control

Mycoplasma, sterility, and adventitious-agent pathways for viral-therapeutic programs.
Release-support documentation

Testing summaries, quality-facing reports, method-validation files where applicable, and release-support documentation for sponsor review.

Sample Types and Deliverables

Sample types

Seed stocks, process intermediates, bulk materials, final release-support samples, and biosafety-investigation samples confirmed during scoping.

Key deliverables

Virus-test summaries, microbial reports, molecular-testing outputs, and sponsor-facing technical documentation.

Scope alignment

Program-specific method design should be confirmed whenever the requested study extends beyond supported biosafety, molecular, and release-support workflows.

Related service use

Oncolytic-virus visitors should be routed into in vitro virus testing, molecular services, microbial testing, lot release, and quality/compliance pages.